NAS:PMD (USA)

Psychemedics Corp

$ 10.51 -0.15 (-1.41%)
On watch
Volume: 12,252 Avg Vol (1m): 35,024
Market Cap $: 57.88 Mil Enterprise Value $: 52.27 Mil
P/E (TTM): 14.80 P/B: 3.15
Earnings Power Value 10.33
Net Current Asset Value 1.16
Tangible Book 3.34
Projected FCF 14.01
Median P/S Value 18.44
Graham Number 7.3
Peter Lynch Value 16.42
DCF (FCF Based) 11.03
DCF (Earnings Based) 9.03
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 4.68
Cash-To-Debt ranked lower than
55.56% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
PMD: 4.68
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.27, Med: 10000, Max: 10000
Current: 4.68
0.27
10000
Equity-to-Asset 0.72
Equity-to-Asset ranked higher than
64.85% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
PMD: 0.72
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.4, Med: 0.81, Max: 0.96
Current: 0.72
0.4
0.96
Debt-to-Equity 0.08
Debt-to-Equity ranked higher than
75.61% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
PMD: 0.08
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.15, Max: 0.83
Current: 0.08
0.01
0.83
Debt-to-EBITDA 0.15
Debt-to-EBITDA ranked higher than
80.17% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
PMD: 0.15
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.15, Med: 0.31, Max: 1.84
Current: 0.15
0.15
1.84
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.76
DISTRESS
GREY
SAFE
Beneish M-Score -2.29
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 29%
WACC 6.01%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 16.00
Operating Margin ranked higher than
89.67% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
PMD: 16
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 5.45, Med: 20.06, Max: 25.94
Current: 16
5.45
25.94
Net Margin % 9.53
Net Margin ranked higher than
89.63% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
PMD: 9.53
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 5.6, Med: 12.41, Max: 17.13
Current: 9.53
5.6
17.13
ROE % 21.25
ROE ranked higher than
97.52% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
PMD: 21.25
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 12.33, Med: 27.12, Max: 48.96
Current: 21.25
12.33
48.96
ROA % 15.04
ROA ranked higher than
95.80% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
PMD: 15.04
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 6.55, Med: 22.36, Max: 28.38
Current: 15.04
6.55
28.38
ROC (Joel Greenblatt) % 50.20
ROC (Joel Greenblatt) ranked higher than
86.10% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
PMD: 50.2
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 9.35, Med: 65.93, Max: 128.25
Current: 50.2
9.35
128.25
3-Year Total Revenue Growth Rate 16.50
3-Year Revenue Growth Rate ranked higher than
66.48% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
PMD: 15.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -10, Med: 9.5, Max: 54.8
Current: 15.6
-10
54.8
3-Year Total EBITDA Growth Rate 50.10
3-Year EBITDA Growth Rate ranked higher than
70.79% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
PMD: 48.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 11.3, Max: 48.8
Current: 48.8
0
48.8
3-Year EPS w/o NRI Growth Rate 43.70
3-Year EPS w/o NRI Growth Rate ranked higher than
65.64% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
PMD: 43.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -3.6, Max: 138.1
Current: 43.7
0
138.1

» PMD's 30-Y Financials

Financials (Next Earnings Date: 2019-07-24)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PMD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare XKRX:217330 NAS:SLNO SGX:1B1 XKRX:031860 ROCO:6615 TPE:4155 ROCO:1784 BOM:524394 OSL:COV TSX:EDT NAS:HTGM XKRX:263690 TSX:PRN XKRX:214610 ASX:CMP NAS:TRIB XKRX:084650 SGX:P8A WAR:VOX LSE:ONC
Traded in other countries
Address 289 Great Road, Acton, MA, USA, 01720
Psychemedics Corp is a US-based company which provides testing services for the detection of drugs of abuse through the analysis of hair samples. The core business of the company is performing drug testing and reporting the results. Its drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The company also provides testimony to support the results of the tests. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The company operates through the single segment being Drug testing services.

Ratios

Current vs industry vs history
PE Ratio (TTM) 14.80
PE Ratio ranked higher than
77.88% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
PMD: 14.8
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 9.07, Med: 19.67, Max: 64.78
Current: 14.8
9.07
64.78
PE Ratio without NRI 14.80
PE without NRI ranked higher than
78.76% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
PMD: 14.8
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 9.07, Med: 19.67, Max: 64.78
Current: 14.8
9.07
64.78
Price-to-Owner-Earnings 14.38
Price-to-Owner-Earnings ranked higher than
82.89% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
PMD: 14.38
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 7.5, Med: 21.09, Max: 144.75
Current: 14.38
7.5
144.75
PB Ratio 3.15
PB Ratio ranked lower than
64.08% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
PMD: 3.15
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.98, Med: 5.41, Max: 9.8
Current: 3.15
1.98
9.8
PS Ratio 1.40
PS Ratio ranked higher than
63.48% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
PMD: 1.4
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.91, Med: 2.46, Max: 3.94
Current: 1.4
0.91
3.94
Price-to-Free-Cash-Flow 10.19
Price-to-Free-Cash-Flow ranked higher than
86.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
PMD: 10.19
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 6.64, Med: 17.95, Max: 74.4
Current: 10.19
6.64
74.4
Price-to-Operating-Cash-Flow 8.46
Price-to-Operating-Cash-Flow ranked higher than
83.51% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
PMD: 8.46
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.92, Med: 14.37, Max: 22.42
Current: 8.46
5.92
22.42
EV-to-EBIT 7.69
EV-to-EBIT ranked higher than
84.75% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
PMD: 7.69
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 4.1, Med: 12.2, Max: 81.9
Current: 7.69
4.1
81.9
EV-to-EBITDA 5.30
EV-to-EBITDA ranked higher than
78.79% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
PMD: 5.3
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 3.7, Med: 10.1, Max: 28.4
Current: 5.3
3.7
28.4
EV-to-Revenue 1.26
EV-to-Revenue ranked higher than
68.60% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
PMD: 1.26
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 2.3, Max: 4
Current: 1.26
0.7
4
PEG Ratio 0.87
PEG Ratio ranked lower than
60.42% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
PMD: 0.87
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.5, Med: 1.38, Max: 132.86
Current: 0.87
0.5
132.86
Shiller PE Ratio 14.13
Shiller PE Ratio ranked higher than
74.36% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
PMD: 14.13
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 5.17, Med: 18.22, Max: 39.85
Current: 14.13
5.17
39.85
Current Ratio 3.08
Current Ratio ranked higher than
53.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
PMD: 3.08
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.67, Med: 4.48, Max: 18.17
Current: 3.08
0.67
18.17
Quick Ratio 3.08
Quick Ratio ranked higher than
58.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
PMD: 3.08
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.56, Med: 4.48, Max: 17.83
Current: 3.08
0.56
17.83
Days Sales Outstanding 45.06
Days Sales Outstanding ranked higher than
78.92% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
PMD: 45.06
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 41.26, Med: 57.01, Max: 70.9
Current: 45.06
41.26
70.9
Days Payable 6.30
Days Payable ranked lower than
95.72% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
PMD: 6.3
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 7.31, Med: 20.53, Max: 36.51
Current: 6.3
7.31
36.51

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 6.85
Trailing Dividend Yield ranked higher than
88.43% of 121 companies
in the Diagnostics & Research industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
PMD: 6.85
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 2.25, Med: 4.68, Max: 18.28
Current: 6.85
2.25
18.28
Dividend Payout Ratio 1.01
Dividend Payout Ratio ranked lower than
67.14% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
PMD: 1.01
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.49, Med: 0.9, Max: 2.14
Current: 1.01
0.49
2.14
3-Year Dividend Growth Rate (Per Share) 4.80
3-Year Dividend Growth Rate ranked lower than
100.00% of 36 companies
in the Diagnostics & Research industry.
Industry Max: 77.2, Med: 9.9, Min: -100
PMD: 4.8
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: -3.1, Max: 26
Current: 4.8
0
26
Forward Dividend Yield % 6.85
Forward Dividend Yield ranked higher than
86.73% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
PMD: 6.85
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 7.55
Yield-on-Cost (5y) ranked higher than
81.69% of 142 companies
in the Diagnostics & Research industry.
Industry Max: 12, Med: 1.41, Min: 0.08
PMD: 7.55
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 2.48, Med: 5.17, Max: 20.18
Current: 7.55
2.48
20.18
3-Year Share Buyback Rate -0.80
3-Year Share Buyback Rate ranked higher than
78.33% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
PMD: -0.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -15.5, Med: -0.6, Max: 1.9
Current: -0.8
-15.5
1.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.15
Price-to-Tangible-Book ranked higher than
51.69% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
PMD: 3.15
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.03, Med: 7.42, Max: 25.49
Current: 3.15
3.03
25.49
Price-to-Projected-FCF 0.75
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
60.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
PMD: 0.75
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.46, Med: 2.42, Max: 21.65
Current: 0.75
0.46
21.65
Price-to-DCF (Earnings Based) 1.16
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
PMD: 1.16
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.5, Med: 1.96, Max: 2.29
Current: 1.16
1.5
2.29
Price-to-Median-PS-Value 0.57
Price-to-Median-PS-Value ranked lower than
53.89% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
PMD: 0.57
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.49, Med: 1.46, Max: 39.82
Current: 0.57
0.49
39.82
Price-to-Peter-Lynch-Fair-Value 0.64
Price-to-Peter-Lynch-Fair-Value ranked higher than
80.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
PMD: 0.64
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.63, Med: 1.3, Max: 16.35
Current: 0.64
0.63
16.35
Price-to-Graham-Number 1.44
Price-to-Graham-Number ranked higher than
71.05% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
PMD: 1.44
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.27, Med: 2.43, Max: 10.79
Current: 1.44
1.27
10.79
Earnings Yield (Joel Greenblatt) % 13.00
Earnings Yield (Greenblatt) ranked higher than
93.21% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
PMD: 13
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.2, Med: 8.2, Max: 24.3
Current: 13
1.2
24.3
Forward Rate of Return (Yacktman) % 27.16
Forward Rate of Return ranked higher than
74.29% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
PMD: 27.16
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -9.6, Med: 6.9, Max: 29.2
Current: 27.16
-9.6
29.2

More Statistics

Revenue (TTM) (Mil) $ 41.56
EPS (TTM) $ 0.71
Beta 0.64
Volatility % 39.76
52-Week Range $ 10.08 - 22.31
Shares Outstanding (Mil) 5.51

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N